Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMYTE6L)

Drug Name

Enoxacin Drug Info

Synonyms

Almitil; Bactidan; Comprecin; Enoram; Enoxacine; Enoxacino; Enoxacinum; Enoxin; Enoxor; Flumark; Penetrex; Enoxacin Sesquihydrate; Enoxacine [French]; Enoxacino [Spanish]; Enoxacinum [Latin]; Faulding Brand of Enoxacin; Pierre Fabre Brand of Enoxacin Sesquihydrate; Rhone Poulenc Rorer Brand of Enoxacin Sesquihydrate; AT 2266; AT2266; CI919; CL23362; E0762; PD 107779; PD107779; AT-2266; Almitil (TN); Bactidan (TN); Bactidron (TN); Comprecin (TN); Enoksetin (TN); Enoxen (TN); Enoxin (TN); Enoxor (TN); Enroxil (TN); Flumark (TN); Gyramid (TN); PD-107779; Penetrex (TN); Rhone-Poulenc Rorer Brand of Enoxacin Sesquihydrate; Sesquihydrate, Enoxacin; Vinone (TN); Enoxacin (USAN/INN); Enoxacin [USAN:BAN:INN:JAN]; 1,8-Naphthyridine-3-carboxylic acid, 6-fluoro-1,4-dihydro-4-oxo-7-piperazinyl; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-1,4-dihydro-4-oxo-7-[1-piperazinyl]-1,8-naphthyridine-3-carboxylic acid; 1-Ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-(piperazin-1-yl)-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid; 1-ethyl-6-fluoro-4-oxo-7-piperazin-1-yl-1,8-naphthyridine-3-carboxylic acid

Indication

Disease Entry	ICD 11	Status	REF
Acute gonococcal cervicitis		Approved	[1]
Urinary tract infection	GC08	Approved	[2]

Therapeutic Class

Antiinfective Agents

Cross-matching ID

PubChem CID: 3229
ChEBI ID: CHEBI:157175
CAS Number: CAS 74011-58-8
TTD Drug ID: DMYTE6L
VARIDT Drug ID: DR01280
ACDINA Drug ID: D01048

Molecule-Related Drug Atlas

Molecule Type:

DTT

DTP

DOT

Drug Status:

Approved Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting DNA topoisomerase II (TOP2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Doxorubicin	DMVP5YE	Acute myelogenous leukaemia	2A41	Approved	[8]
Etoposide	DMNH3PG	Acute myelogenous leukaemia	2A41	Approved	[9]
Teniposide	DMLW57T	Acute lymphoblastic leukaemia	2A85	Approved	[8]
Mitoxantrone	DMM39BF	Acute myelogenous leukaemia	2A41	Approved	[10]
Idarubicin	DMM0XGL	Acute myelogenous leukaemia	2A41	Approved	[8]
Epirubicin	DMPDW6T	Solid tumour/cancer	2A00-2F9Z	Approved	[8]
Lomefloxacin	DMVRH9C	Bacterial infection	1A00-1C4Z	Approved	[11]
Dexrazoxane	DMD7X1O	Breast cancer	2C60-2C65	Approved	[8]
Podofilox	DMT2EJP	Condyloma	1A95	Approved	[12]
Amsacrine	DMZKYIV	Acute lymphoblastic leukaemia	2A85	Approved	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Multidrug and toxin extrusion protein 1 (SLC47A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aciclovir	DMYLOVR	Genital herpes	1A94	Approved	[14]
Metformin	DM89QE1	Colorectal carcinoma		Approved	[15]
Ganciclovir	DM1MBYQ	Cytomegalovirus infection	1D82	Approved	[14]
Cimetidine	DMH61ZB	Acid-reflux disorder	DA22	Approved	[14]
Chloroquine	DMSI5CB	Malaria	1F40-1F45	Approved	[16]
Procainamide	DMNMXR8	Ventricular arrhythmias	BC71	Approved	[14]
Topotecan	DMP6G8T	Central nervous system neoplasm		Approved	[14]
Cephalexin	DMD5JU8	Acute otitis media	AB00	Approved	[17]
LY2835219	DM93VBZ	Breast cancer	2C60-2C65	Approved	[18]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[19]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Transported By Organic anion transporting polypeptide 1A2 (SLCO1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Methotrexate	DM2TEOL	Anterior urethra cancer		Approved	[20]
Dinoprostone	DMTYOPD	Medical abortion	JA00.1Z	Approved	[21]
Imatinib	DM7RJXL	Acute lymphoblastic leukaemia	2A85	Approved	[22]
Atorvastatin	DMF28YC	Acute coronary syndrome	BA41	Approved	[23]
PITAVASTATIN CALCIUM	DM1UJO0	Dyslipidemia	5C80-5C81	Approved	[24]
Rosuvastatin	DMMIQ7G	Arteriosclerosis	BD40	Approved	[25]
Saquinavir	DMG814N	Human immunodeficiency virus infection	1C62	Approved	[26]
Enalapril	DMNFUZR	Congestive heart failure	BD10	Approved	[27]
Cholic Acid	DM7OKQV	Cholelithiasis	DC11	Approved	[28]
Liothyronine	DM6IR3P	Congenital hypothyroidism		Approved	[29]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Zolmitriptan	DM1IB4Q	Migraine	8A80	Approved	[30]
Rofecoxib	DM3P5DA	Osteoarthritis	FA00-FA05	Approved	[30]
Etoricoxib	DM6A4NW	Rheumatoid arthritis	FA20	Approved	[30]
Capsaicin	DMGMF6V	Back pain	ME84.Z	Approved	[31]
Hesperetin	DMKER83	High blood cholesterol level	5C80.00	Approved	[32]
Stiripentol	DMMSDOY	Dravet syndrome	8A61.11	Approved	[33]
Nifedipine	DMSVOZT	Angina pectoris	BA40	Approved	[34]
Zileuton	DMVRIC2	Allergic asthma	CA23.0	Approved	[35]
Nicotine	DMWX5CO	Lung cancer	2C25.0	Approved	[36]
Clonidine	DM6RZ9Q	Attention deficit hyperactivity disorder	6A05.Z	Approved	[37]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Affected By Potassium voltage-gated channel subfamily H member 2 (KCNH2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Metoclopramide	DMFA5MY	Nausea	MD90	Approved	[38]
Quinidine	DMLPICK	N. A.	N. A.	Approved	[39]
Verapamil	DMA7PEW	Angina pectoris	BA40	Approved	[40]
Erythromycin	DM4K7GQ	Acne vulgaris	ED80	Approved	[41]
Clarithromycin	DM4M1SG	Acute maxillary sinusitis		Approved	[41]
Disopyramide	DM5SYZP	Long QT syndrome	BC65.0	Approved	[42]
Propranolol	DM79NTF	Angina pectoris	BA40	Approved	[43]
Amiodarone	DMUTEX3	Tachyarrhythmias	BC71	Approved	[44]
Dofetilide	DMPN1TW	Sinus rhythm disorder	BC9Y	Approved	[45]
Flecainide	DMSQDLE	Tachyarrhythmias	BC71	Approved	[41]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
DNA topoisomerase II (TOP2)	TT0IHXV	TOP2A_HUMAN; TOP2B_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Organic anion transporting polypeptide 1A2 (SLCO1A2)	DTE2B1D	SO1A2_HUMAN	Substrate	[4]
Multidrug and toxin extrusion protein 1 (SLC47A1)	DTZGT0P	S47A1_HUMAN	Substrate	[5]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Cytochrome P450 1A2 (CYP1A2)	OTLLBX48	CP1A2_HUMAN	Gene/Protein Processing	[6]
Potassium voltage-gated channel subfamily H member 2 (KCNH2)	OTZX881H	KCNH2_HUMAN	Protein Interaction/Cellular Processes	[7]

------------------------------------------------------------------------------------

References

1	Enoxacin FDA Label
2	FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 019616.
3	Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
4	Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
5	Functional characterization of multidrug and toxin extrusion protein 1 as a facilitative transporter for fluoroquinolones. J Pharmacol Exp Ther. 2009 Feb;328(2):628-34.
6	Interaction study between enoxacin and fluvoxamine. Ther Drug Monit. 2005 Jun;27(3):349-53.
7	Computational and experimental studies on the inhibitory mechanism of hydroxychloroquine on hERG. Toxicology. 2021 Jun 30;458:152822. doi: 10.1016/j.tox.2021.152822. Epub 2021 May 28.
8	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
9	Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
10	Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
11	Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
12	Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
13	Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21.
14	Substrate specificity of MATE1 and MATE2-K, human multidrug and toxin extrusions/H(+)-organic cation antiporters. Biochem Pharmacol. 2007 Jul 15;74(2):359-71.
15	Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010 Apr;298(4):F997-F1005.
16	Molecular mechanism of renal tubular secretion of the antimalarial drug chloroquine. Antimicrob Agents Chemother. 2011 Jul;55(7):3091-8.
17	Reduced renal clearance of a zwitterionic substrate cephalexin in MATE1-deficient mice. J Pharmacol Exp Ther. 2010 Aug;334(2):651-6.
18	Abemaciclib Inhibits Renal Tubular Secretion Without Changing Glomerular Filtration Rate. Clin Pharmacol Ther. 2019 May;105(5):1187-1195.
19	FDA Drug Development and Drug Interactions
20	Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
21	Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
22	Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
23	Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
24	Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
25	Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
26	Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
27	Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
28	Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
29	Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
30	In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
31	Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
32	Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
33	Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
34	Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
35	Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
36	Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
37	ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
38	Comparison of the effects of metoclopramide and domperidone on HERG channels. Pharmacology. 2005 Apr;74(1):31-6. doi: 10.1159/000083234. Epub 2005 Jan 7.
39	Further insights into the effect of quinidine in short QT syndrome caused by a mutation in HERG. J Cardiovasc Electrophysiol. 2005 Jan;16(1):54-8. doi: 10.1046/j.1540-8167.2005.04470.x.
40	Automated tight seal electrophysiology for assessing the potential hERG liability of pharmaceutical compounds. Assay Drug Dev Technol. 2004 Oct;2(5):497-506. doi: 10.1089/adt.2004.2.497.
41	Refining the human iPSC-cardiomyocyte arrhythmic risk assessment model. Toxicol Sci. 2013 Dec;136(2):581-94. doi: 10.1093/toxsci/kft205. Epub 2013 Sep 19.
42	Pharmacology of the short QT syndrome N588K-hERG K+ channel mutation: differential impact on selected class I and class III antiarrhythmic drugs. Br J Pharmacol. 2008 Nov;155(6):957-66. doi: 10.1038/bjp.2008.325. Epub 2008 Aug 25.
43	Comparison of HERG channel blocking effects of various beta-blockers-- implication for clinical strategy. Br J Pharmacol. 2006 Mar;147(6):642-52. doi: 10.1038/sj.bjp.0706508.
44	Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels. Naunyn Schmiedebergs Arch Pharmacol. 1999 Mar;359(3):212-9. doi: 10.1007/pl00005344.
45	Redox state dependency of HERGS631C channel pharmacology: relation to C-type inactivation. FEBS Lett. 2000 May 26;474(1):111-5. doi: 10.1016/s0014-5793(00)01586-6.